
Revenue of Abilify globally by region 2011-2016
This statistic displays the global revenue of Abilify from Bristol-Myers Squibb by region from 2011 to 2016. In the United States alone, BMS generated a revenue of 2.1 billion U.S. dollars with Abilify in 2012. In 2016, due to patent expiration, Abilify generated revenues only outside the United States. Abilify is an antipsychotic agent that is used to treat various conditions such as schizophrenia, bipolar mania disorder, and major depressive disorder.